| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
BridgeBio Pharma Inc (NASDAQ: BBIO)
BBIO Technical Analysis
3
| As on 9th Jun 2023 BBIO STOCK Price closed @ 16.00 and we RECOMMEND Buy for LONG-TERM with Stoploss of 10.40 & Buy for SHORT-TERM with Stoploss of 12.89 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BBIOSTOCK Price
| Open | 16.29 | Change | Price | % |
| High | 16.36 | 1 Day | -0.29 | -1.78 |
| Low | 15.89 | 1 Week | 2.28 | 16.62 |
| Close | 16.00 | 1 Month | 1.81 | 12.76 |
| Volume | 1207600 | 1 Year | -26.36 | -62.23 |
| 52 Week High 42.36 | 52 Week Low 5.21 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| BBIO Daily Charts |
BBIO Intraday Charts |
Whats New @ Bazaartrend |
BBIO Free Analysis |
|
|
BBIO Important Levels Intraday
| RESISTANCE | 16.91 |
| RESISTANCE | 16.62 |
| RESISTANCE | 16.44 |
| RESISTANCE | 16.26 |
| SUPPORT | 15.74 |
| SUPPORT | 15.56 |
| SUPPORT | 15.38 |
| SUPPORT | 15.09 |
BBIO Forecast May 2024
| 4th UP Forecast | 29.86 |
| 3rd UP Forecast | 25.41 |
| 2nd UP Forecast | 22.67 |
| 1st UP Forecast | 19.92 |
| 1st DOWN Forecast | 12.08 |
| 2nd DOWN Forecast | 9.33 |
| 3rd DOWN Forecast | 6.59 |
| 4th DOWN Forecast | 2.14 |
BBIO Weekly Forecast
| 4th UP Forecast | 29.35 |
| 3rd UP Forecast | 25.07 |
| 2nd UP Forecast | 22.42 |
| 1st UP Forecast | 19.78 |
| 1st DOWN Forecast | 12.22 |
| 2nd DOWN Forecast | 9.58 |
| 3rd DOWN Forecast | 6.93 |
| 4th DOWN Forecast | 2.65 |
BBIO Forecast2024
| 4th UP Forecast | 87.38 |
| 3rd UP Forecast | 64.49 |
| 2nd UP Forecast | 50.34 |
| 1st UP Forecast | 36.19 |
| 1st DOWN Forecast | -4.19 |
| 2nd DOWN Forecast | -18.34 |
| 3rd DOWN Forecast | -32.49 |
| 4th DOWN Forecast | -55.38 |
BridgeBio Pharma Inc ( NASDAQ USA Symbol : BBIO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BBIO Business Profile
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.; the University of California, San Diego; Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; UC San Francisco; the Canadian Glycomics Network (GlycoNet); the University of California; and Helsinn Group, as well as a clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398. It also has a research collaboration and option agreement with Unnatural Products Inc. to target rare diseases with potential oncology applications. The company was founded in 2015 and is headquartered in Palo Alto, California. Address: 421 Kipling Street, Palo Alto, CA, United States, 94301
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service